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Human thymosin alpha 1 (Tα1) is an important peptide in the development and senescence of immunological competence in
human, and many studies have reported the expression of this peptide. In this study, we designed and synthesized the Tα1g e n e
according to the E. coli codon usage preference and constructed a 6×Tα1 concatemer. The latter was inserted into an E. coli
expression vector pET-22b (+), and transformed into E. coli BL21 (DE3). After induction with IPTG, the concatemer protein was
successfullyexpressedinE.colithencleavedbyhydroxylaminetoreleasetheTα1monomer.Gly-SDS-PAGEandmassspectrometry
conﬁrmedthattherecombinantproteinwascleavedasintended.ThebioactivityoftheTα1monomerwasanalyzedbylymphocyte
proliferation and by mitochondrial activity in two diﬀerent tumor cell lines. This study provides a description of the preparation
of a bioactive Tα1, which may prove useful in future biomedical research.
Copyright © 2008 Liang Zhou et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Thymosin alpha 1 (Tα1), a 28-amino-acid peptide with
molecular weight (MW) of 3108Da, was ﬁrst isolated from
calf thymus in 1977 by Goldstein et al. [1, 2]. Tα1 is mainly
producedinvivobythymicepithelialcellsandisstableat80–
90◦C[ 3]. Tα1 has no aromatic amino acids (see Figure 1),
and N-acetylation is important for protecting towards prote-
olysis.Tα1playsaroleagainstviralinfection,againsttumors,
and in immunomodulation. Upon stimulation of Tα1, T
c e l l sb e c o m em a t u r ei nv i t r oa n de x p r e s sI L - 2 ,I L - 2 R ,a n d
CD2 [4, 5]. Tα1 inhibits viral replication at least in hepatitis
virus B-transfected HepG2 tumor cells [6, 7]. In addition,
Tα1 antagonizes T cell apoptosis induced by dexamethasone,
CD3 monoclonal antibody treatment [8], or addition of sera
from tumor-bearing mice [9]. It also downregulates tumor
weight in mice [10], enhances major histocompatibility
complex(MHC)classIantigenexpressionintumorcellsand
antigen-presenting cells [11–13], and partly restores cellular
immunity [14]. Tα1 is used in combination with IFN-α for
patientswithchronichepatitisvirusBorCinfection[15,16].
Tα1 is used to reduce adverse eﬀects from chemotherapy or
radiotherapy [17]. Recently, Tα1 has even been used as an
adjuvant for vaccines against inﬂuenza and hepatitis B [18].
In the past two decades, although the successful expres-
sion of the recombinant Tα1( rT α1) and Prothymosin
(thymosin comprises the N-terminus of Prothymosin) in
Escherichia coli h a sb e e nr e p o r t e d[ 19, 20]. However, Tα1
was expressed with a fusion protein or in a concatemer
form [21, 22]. The expression of the Tα1 monomer peptide
has not been reported, because it is diﬃcult to extract the
micromolecular peptide from the fermentation broth. The
fusionproteinmustberemovedbecausefusionproteincould
inﬂuence the bioactivity of the peptide. The concatemer
protein has not been processed further. All of these issues
made it diﬃcult to prepare active recombinant Tα1. In this
study,wehaveexpressedTα1concatemerproteinandcleaved
the concatemer protein with hydroxylamine to obtain active
Tα1 monomer peptide.
2. MATERIALS AND METHODS
2.1. Materials
The pET-22b (+) vector, E. coli BL21 (DE3) (hsdS gal
[λcIts857 ind1 Sam7 nin5 lacUV5-T7]), the HepG2 liver
carcinoma cell line, and the SPC-A-1 lung carcinoma cell
line were kindly provided by Institute of Biochemistry2 Journal of Biomedicine and Biotechnology
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Figure 1: The complete amino acid sequence of Tα1.
and Cell biology (Shanghai, CAS, China). E. coli BL21
cells were maintained in Luria-Bertani (LB). HepG2 and
SPC-A-1 cells were cultured in RMPI 1640 medium with
10% fetal bovine serum in humidiﬁed air at 37◦Cw i t h
5% CO2. Lymphocytes were isolated from adult mouse
spleens (BAL/C) and cultured in RMPI 1640 medium with
10% fetal bovine serum in humidiﬁed air at 37◦Cw i t h
5% CO2. Synthesized Tα1 (Sinopep Pharmaceutical, Inc.,
Hangzhou, China.) was supplied as puriﬁed, endotoxin-free.
The synthesized Tα1 and the cleaved Tα1 were dissolved
in phosphate-buﬀered solution (PBS pH 7.2) at 1mg/mL
(approximately 3 × 10
−8 mol/L) and then sterilized with a
0.22μm ﬁlter.
2.2. SynthesisoftheTα1concatemer
Two single strand DNA oligomers encoding the entire
thymosin alpha peptide (synthesized by Songon, Shanghai,
China.), partially complementary to each other (as indicated
by the underlined sequences) were synthesized. We used
codons that were preferred in E. coli.
THY-F: GTCGACATGGGATCCAACGGTTCT-
GATGCTGCTGTAGATACTTCTTCTGAGAT
TACTACTAAAGACCTAA
THY-R: CTCGAGTCAAGATCTCCCGTTCT-
CAGCCTCTTCGACAACTTCCTTCTTCTCCT
TTAGGTCTTTAGTAGTA
The 2 oligonucleotides were mixed and denatured by
incubation at 94◦C for 10 minutes, and subsequently
annealed at 60◦C for 10 minutes in presence of TaqPlus
(BBI, Toronto, Canada). The desired double-strand DNA
was treated with T4 polynucleotide kinase (BBI, Toronto,
Canada) and cloned into the cloning vector pUCm-T (BBI,
Toronto, Canada).
The plasmid (pUCm-T-Tα1, pT-Tα1) containing the
Tα1 gene was digested with BamH I/Xho Io rBgl II/Xho I,
respectively. The digested fragments containing the coding
sequence of Tα1 were ligated with T4 DNA Ligase for 16
hours at 4◦C to produce the concatemer Tα1 gene of 2
repeats (pT-Tα1×2). When the plasmid was digested with
isocaudamer BamHI (G∗CTAG C) and Bgl II (A∗GATC T),
the 2 fragments had similar termini. When the 2 fragments
werecatalyzedwithT4DNALigasethenewsequenceformed
was GGATCT, and this new site could not be digested by
BamH I or Bgl II (see Figure 2).
Using a pT-Tα1×2 plasmid, plasmids containing con-
catemer4repeats(pT-Tα1×4)oftheTα1genewereprepared
as described above. Using a pT-Tα1×2 plasmid and a pT-
pT-Tα1
2700 bp
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2800 bp
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Figure 2: Construction of the concatemer Tα1g e n e .AT - v e c t o r
containing the Tα1 gene was digested with BamH I/Xho Ia n dBgl
II/Xho I. When digested with Bgl II and BamH I, the 2 fragments
have identical termini. The two fragments containing the Tα1 gene
were ligated with T4 DNA Ligase. A plasmid containing double Tα1
genes was constructed. When the 2 fragments were catalyzed with
T4 DNA Ligase, the new sequence formed was GGATCT, and this
new site could not be digested by BamH I or Bgl II. Therefore,
the new 2× concatemer gene could not be destroyed when the 4×
concatemergenewasconstructed.Thus,theplasmidcontaining4×,
6× Tα1 genes could also be constructed.
Tα1×4 plasmid, the preparation of plasmids containing
concatemer 6 repeats (pT-Tα1×6) was the same as pT-
Tα1×2 plasmid.
Finally, a fragment containing the concatemer Tα1 gene
of 6 repeats was constructed and inserted into expression
vector pET-22b (+), between the restriction endonuclease
recognition sites Hind III and Nde I.
2.3. Expressionandpuriﬁcationof
Tα1concatemerprotein
A single bacterial colony containing pET-22b (+)-Tα1w a s
grown overnight at 37◦C in 5mL LB medium with 50μg/mLLiang Zhou et al. 3
GS  N GSDAAVSTSSEITTKDLKEKKEVVEEAEN GRS
N GSDAAVSTSSEITTKDLKEKKEVVEEAEN GRS
N GSDAAVSTSSEITTKDLKEKKEVVEEAEN GRS
N GSDAAVSTSSEITTKDLKEKKEVVEEAEN GRS
N GSDAAVSTSSEITTKDLKEKKEVVEEAEN GRS
N GSDAAVSTSSEITTKDLKEKKEVVEEAEN GRS
Figure 3: The sequence and hydroxylamine cleavage sites of the
concatemer protein. The concatemer protein contained a total of
200 amino acids, and the molecular weight of the concatemer
protein was approximately 23kD. The 6 × Tα1 sequence is
underlined, and the cleavage sites Asn-Gly are indicated with a
vertical arrow.
Ampicillin (BBI, Toronto, Canada). The overnight culture
was inoculated into 250mL LB medium in a 1L ﬂask
with 50μg/ml Ampicillin. After 2 hours of incubation,
isopropyl-1-thio-beta-D-galactoside (IPTG; BBI, Canada)
was added to the culture at a ﬁnal concentration of 1.0mM,
when the cell density had reached OD600nm = 0.6. After
incubation at 37◦C for 8 hours, the bacterial cells were
harvested by centrifugation (5000 × g,1 5m i n u t e s )a t4 ◦C.
The inducibility of the concatemer gene was determined
bysodiumdodecylsulfate-polyacrylamidegelelectrophoresis
(SDS-PAGE) (data not shown).
T h ec e l lp e l l e tw a sr e s u s p e n d e di n1 0 0 m Lb u ﬀer A
(50mM Tris-HCl [pH 8.0], 1mM EDTA [pH 8.0], and
0.1M NaCl) and then sonicated (800W, 20 minutes).
After sonication, the sedimented material (containing the
concatemer protein) was washed once ﬁrst with 100mL
buﬀer B (50mM Tris-HCl [pH 8.0], 1mM EDTA (pH 8.0),
and 0.5% Triton-X 100) and then with 100mL buﬀer C
(50mM Tris-HCl [pH 8.0], 1mM EDTA (pH 8.0), and 2M
urea) by centrifugation. The sedimented material was then
dissolved in 100mL buﬀer D (50mM Tris-HCl [pH 8.0],
1mM EDTA [pH 8.0], and 8M urea) with stirring for 1
hourat25◦C.Thesolubleproteinwasthendialyzed(Dialysis
Membrane MWCO 10000, SPECTRUM, Tex, USA) with
double distilled H2O and cryodesiccated.
2.4. Hydroxylaminecleavagereactionand
analysisofcleavageproducts
The concatemer protein was then cleaved with hydrox-
ylamine. The cleavage sites are shown in Figure 3.T h e
cleavage buﬀer [21] contained 0.1M trizma base and 2.0M
hydroxylamine-HCl. The pH of the cleavage buﬀer was
adjusted with 5M NaOH solution to a pH of 9.0, and the
reaction was performed at 45◦C for 4 hours. The reaction
was terminated by adjusting the pH to 4.0 with concentrated
formic acid and cooling to 4◦C[ 21]. Using Sephadex-G25
(GE) column chromatography, the products of cleavage were
desalted. Column chromatography revealed 2 peaks; one
peak corresponded to the Tα1 monomer and the other
contained the incompletely cleaved concatemer protein. The
molecular mass of the Tα1 monomer was analyzed by Gly-
SDS-PAGE and mass spectrometry.
2.5. Assayforproliferationofmice
spleniclymphocytes
The proliferation response of splenocytes was determined
by MTT assay [23]. Spleens were removed from mice and
dispersed through nylon mesh to generate a single-cell
suspension. Cells were pelleted (1500 × g,6m i n u t e s ) ,a n d
the cell pellet was resuspended in erythrocyte lysis solution
(0.15M NH4C l ,0 . 0 2MT r i s ,s t e r i l i z e dw i t ha0 . 2 2μm ﬁlter)
for 5 minutes to remove the red cells. After lysis, the cell
suspension was incubated in a culture ﬂask for 2 hours, and
then the suspension was transferred to a new ﬂask. Splenic
macrophages adhered to the ﬂask; this procedure enriched
for lymphocytes.
Splenic lymphocytes were incubated in RPMI 1640
medium with 5μg/mL concanavalin A (ConA; BBI, Canada)
for 12 hours, and then harvested by centrifugation (1500×
g, 6 minutes). The cell pellet was resuspended in RPMI
1640 medium at a concentration of 1 × 106 cells/mL. A 96-
well culture plate (Costar, Inc., Calif, USA) was used for
incubation of 180μL lymphocytes in RPMI 1640 medium.
50μg/mL of the proteins (cleaved Tα1 and synthesized Tα1)
wereaddedtothewells.After24-houror48-hourincubation
at 37◦C, 20μL of MTT (0.5mg/mL), solution was added to
each well, and the microplates were incubated for 4 hours at
37◦C. After incubation, the plates were centrifuged (1400 ×
g,1 8 ◦C, 10 minutes). The supernatants were removed, and
200μL of dimethyl sulfoxide (DMSO) was added to each
well and incubated for 15 minutes at room temperature.
Afterincubation,thesolubilizedreducedMTTwasmeasured
colorimetrically at 570nm using a Benchmark microculture
plate reader (Bio-Rad, Calif, USA).
2.6. Assayformitochondrialactivityof
HepG2andSPC-A-1cells
The inﬂuence of Tα1 on mitochondrial activity was mea-
sured using MTT reduction, a common experimental
method to quantify mitochondrial activity. The cells were
seeded in a 96-well culture plate at 1 × 106 cells/mL. After
24-hour, 48-hour, and 72-hour exposures to Tα1a tac o n -
centration of 0.1mg/mL, the cells were incubated with MTT
(0.5mg/mL) for 4 hours at 37◦C. The formazan precipitate
was then dissolved in 200μL DMSO, and absorbance at
570nm was measured using the Benchmark microculture
plate reader (Bio-Rad, Calif, USA).
2.7. Statisticanalysis
Thedataarepresentedasmean ±SEM,foratleast3replicate
experiments and evaluated using the Student’s t-test. P-
values below 0.05 were regarded as statistically signiﬁcance
(two-tailed test).
3. RESULTS
Hydroxylamine-induced cleavage at the Asp-Gly dipeptide
site inserted between the 2 moieties of recombinant fusion
p r o t e i n sh a db e e nu s e df o rb o t ha n a l y s i sa n dp r e p a r a t i o no f4 Journal of Biomedicine and Biotechnology
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Figure 4: Overexpression of the recombinant concatemer protein. (a) Lane 1: prestained molecular mass markers. Lanes 2 and 3: full
bacterial protein from 100μL transformed cells after 1.0mM and 0.5mM IPTG induction for 8 hours at 37◦C. Lane 4: full bacterial protein
from 100μL transformed cells without induction of IPTG for 8 hours at 37◦C. (b) Lane 1: prestained molecular mass markers. Lane 2: full
bacterial protein from 100μL transformed cells after 1.0mM IPTG induction for 8 hours. Lane 3: sedimented material from Sonication of
100μL transformed cells after induction with IPTG. Lane 4: suspended material from Sonication of 100μL transformed cells after induction
with IPTG.
mature protein. Cleavage occurs at the Asn-Gly bonds and
results from the tendency of the Asp side chain to cyclize
the formation of a substituted succinimide that is susceptible
to nucleophilic attack by hydroxylamine. The infrequency of
Asn-Gly bonds in most proteins results in the production
of very large fragments that may overlap CNBr-produced
fragments [24]. In the complete amino acid sequence of Tα1
[1] (see Figure 1), only 1 Asp was found at the C-terminus.
However, the hydroxylamine-induced cleavage process was
performed conveniently. Hydroxylamine-induced cleavage
is high speciﬁcity and safe, however, the eﬃciency of
hydroxylamine cleavageis low.Sowe expressedaconcatemer
p r o t e i no f6r e p e a t so fT α1t oi n c r e a s et h ey i e l do fT α1a f t e r
cleavage and to decrease the cleavage sites.
3.1. Characterizationofrecombinant
concatemerprotein
The optimal conditions for inducing production of recom-
binant concatemer protein were at an IPTG concentration
of 1.0mM 37◦C for 8 hours. Under these conditions,
the recombinant protein (∼23kD) comprised 31% of the
total bacterial protein (see Figure 4(a)). The concatemer
protein was identiﬁed primarily in the inclusion bodies (see
Figure 4(b)).
3.2. Analysisoftheproductsof
hydroxylaminecleavage
G-25 column chromatography was used to not only desalt
but also remove the incompletely cleaved concatemer pro-
tein. Because the molecular weight of the Tα1 monomer
was ∼3.1kD, it could enter the G-25 gel. However,
the incompletely cleaved concatemer proteins, including
2×Tα1( ∼7kD),3×Tα1( ∼11kD), 4×Tα1( ∼15kD),5×Tα1
(∼19kD), and 6×Tα1( ∼23kD), could not enter the G-
25 gel because the gel only allows the entry of molecules
<5kD. The Gly-SDS-PAGE could satisfactorily separate
123
Figure 5: Analysis of hydroxylamine cleavage products. Lane 1:
peak 1 of G-25 column chromatography revealed the protein with
a molecular weight of more than 5kD that was eluted early. Lane
2: peak 2 of G-25 column chromatography containing the protein
with a molecular weight of less than 5kD that was eluted later. Lane
3: the Tα1 synthesized as a standard protein.
polypeptides with molecular weights ranging from 3.5 to
68.0kD with good linearity, and demonstrated the successful
hydroxylamine-induced cleavage of the concatemer proteins
(see Figure 5). However, not all the concatemer proteins
were cleaved, and the incompletely cleaved proteins could be
completely cleaved by another reaction (data not shown).
MS was performed to analyze the exact molecular
weights of the products and the synthesized Tα1. The result
showed that the products had only 1 peak of m/z =1042.19,
while the synthesized Tα1h a d2p e a k so fm / z= 1037.80
and 1555.06 (see Figure 6). The molecular weight of the
synthesized Tα1 was found to be approximately 3108Da, itLiang Zhou et al. 5
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Figure 6: (a) Mass spectrum of the cleaved Tα1. The attachment of 3 protons per peptide molecule leads to only 1 of m/z peak; m/z =
1042.19. (b) Mass spectrum of the synthesized Tα1. The attachment of 2 and 3 protons per peptide molecule leads to 2 peaks of m/z =
1037.80 and 1555.06.
was assumed that the peptide might attach 2 or 3 protons
[(1037.80−1) × 3 = 3110.4; (1555.06−1) × 2 = 3108.12].
Therefore, the cleaved Tα1 was believed to attach 3 protons,
and the molecular weight of the products was approximately
3123.57 [(1042.19-1) × 3 = 3123.57]. The diﬀerence in
the molecular weights between the cleaved Tα1 and the
synthesized Tα1 was approximately 15. According to a
previous research [24], the structural diﬀerence between the
products and the synthesized Tα1w a sa– N Ha d d e dt ot h e
N-terminus of the cleaved peptide (see Figure 9).
3.3. Tα1cleavedbyhydroxylaminestimulatedthe
proliferationofmicespleniclymphocytes
To determine the bioactivity of the Tα1 monomer on
lymphocyte proliferation, the mitochondrial activity was
compared in the presence with the absence of the Tα1. The
bioactivity of Tα1 preparations was analyzed by MTT assay.
Preliminary results showed that the peptides could stimulate
the mice spleen lymphocyte proliferation [22]. After a
24-hour treatment with Tα1 cleaved by hydroxylamine,
mitochondrial activity was upgraded to 119.1% and after
48 hours, it was 110.4%.The numbers of the synthesized
Tα1 were 117.5% and 116.0% at 24 hours and 48 hours,
respectively (see Figure 7). Both of the peptide preparations
could stimulate the proliferation of mice spleen lymphocytes
to a similar degree.
3.4. Tα1cleavedbyhydroxylamineexhibitsdecreased
mitochondrialactivityinSPC-A-1andHepG2cells
In this study, we used human liver tumor cells HepG2 and
human lung tumor cells SPC-A-1 as model, because the
liver tumor and lung tumor are the most general tumor. To
determine the role of mitochondria during incubation, the
mitochondrial activity was examined. After the treatment
with the cleaved Tα1 for 24 hours, 48 hours, and 72 hours,
the mitochondrial activity of the SPC-A-1 cells decreased to
82.4%, 27.1%, 11.6%, respectively, and the corresponding
activities with synthesized Tα1 were 62.0%, 15.1%, and
9.8%, respectively. On the other hand, after the treatment
for 24 hours, 48 hours, and 72 hours, the mitochondrial
activity of HepG2 cells decreased to 86.6%, 18.4%, and
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Figure 7: Tα1 (cleaved and synthesized) stimulated the prolifera-
tion of mice spleen leukomonocytes. The mice spleen leukomono-
cytes were treated with the indicated concentrations of Tα1f o r
24 hours, and 48 hours. MTT assay was used to measure the
mitochondrialactivity.Signiﬁcantstimulationofthemitochondrial
activity, as compared to the control, occurred after 48 hours of
Tα1 treatment. All the results are expressed as the mean ± SEM
of data obtained in 3 independent experiments (P<. 05, relative to
control).
10.4%, respectively, and corresponding activities with the
synthesized Tα1 were 59.2%, 13.1%, and 10.0%, respectively
(see Figure 8). Both of the peptide preparations decreased
the mitochondrial activity remarkably, as compared to the
control. The diﬀerence in the activity between the 2 peptides
was not signiﬁcant; however, the process of synthesizing Tα1
was rather intricate.
4. DISCUSSION
TherequirementsofTα1forclinicalapplicationsareincreas-
ing. For clinical use, Tα1 is mainly obtained by chemical
synthesis and animal thymus extraction. However, in fact,
Tα1 from an animal is often impure and may therefore cause6 Journal of Biomedicine and Biotechnology
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Figure 8: Tα1 (cleaved and synthesized) induced a decrease in the mitochondrial activity in the SPC-A 1 and HepG2 cells. (a) The SPC-
A1 cells were treated with the indicated concentrations of Tα1 for 24 hours, 48 hours, and 72 hours. MTT assay was used to measure
the mitochondrial activity. Signiﬁcant decreases in the mitochondrial activity, as compared to the control, occurred after 48 hours of Tα1
treatment. (b) The HepG2 cells were treated with the indicated concentrations of Tα1 for 24 hours, 48 hours, and 72 hours. MTT assay was
used to measure the mitochondrial activity. Signiﬁcant decreases in the mitochondrial activity, as compared to the control, occurred after 48
hours of Tα1 treatment. All the results are expressed as the mean ± SEM of data obtained in 3 independent experiments (P<. 05, relative to
control).
NH2 −CH2 −CO−Tα1
(a) Cleaved Tα1
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Figure 9: Diﬀerences in the structures of the synthesized Tα1a n d
the cleaved Tα1.
heterogeneous allergy. Although chemically synthesized Tα1
can reach a high level of purity, it is necessary to eliminate
the side products at each step, including incorrect joining
and dextral compounds. The longer the peptide is, the
more intricate the chemical synthesis process becomes. Tα1
comprises 28 amino acid residues, and its chemical synthesis
incurs a high production cost [19]. Prokaryotic expression
systems allow for high expression of foreign genes and are
widely used for producing large amounts of proteins or
peptides. In this research, using a prokaryotic expression
system BL21 (DE3)/pET-22b (+), we have established a new
method to obtain relatively pure and large quantities of Tα1.
When the plasmid was digested with isocaudamer BamH
I( G ∗CTAG C) and Bgl II (A∗GATC T), the 2 fragments had
similar termini. When the 2 fragments were catalyzed with
T4 DNA Ligase, the new sequence formed was GGATCT, and
this new site could not be digested by BamH I or Bgl II (see
Figure 2). Therefore, the new 2 × concatemer gene could not
bedestroyedwhenthe4 ×concatemergenewasconstructed.
The new site GGATCT corresponded to the dipeptide Gly-
Ser, located at the downstream of the Tα1 gene. When con-
catemer protein was cleaved with hydroxylamine, the down-
stream amino acid of Tα1 peptide was removed from this
Glysite.Whenthecleavagereactionproceeded,theupstream
amino acid of Tα1 peptide was removed from another Gly
site, which was added in front of the Tα1p e p t i d e .
It is common knowledge that extraction of the micro-
molecular recombinant peptide from fermentation broth is
diﬃcult, when Tα1 is expressed alone. Generally, a fusion
protein is used under these circumstances, for example, a
DsbA fusion protein [25]. However, the fusion protein must
be removed because the peptide might be inactive, and
this process incurs a high production cost. The concatemer
protein of 6 repeats—6×Tα1—was prepared in this research
to avoid the use of a fusion protein when expressing the
recombinant protein, but the number of the repeats was not
unique. Proteins with 4, 8, 12, and so forth repeats could also
be constructed. The longer the concatemer protein is, the
greater the yield of the Tα1 monomer is. On the other hand,
when a concatemer protein with more repeats is cleaved, the
amount of the incompletely cleaved protein also increases
(see Figure 5). However, these incompletely cleaved proteins
can be cleaved by other 1 or 2 rounds of hydroxylamine
cleavage.
Hydroxylamine was used to cleave the Asn-Gly peptide
bond between the fusion protein and target protein [26]. In
this study, hydroxylamine was used to cleave the concatemer
protein of 6×Tα1 to release the Tα1 monomer. While
chemical cleavage methods use relatively inexpensive and
widely available reagents, cleavage conditions are often
relatively harsh and amino acid side-chain modiﬁcationsLiang Zhou et al. 7
may occur. This is especially true when hydroxylamine is
used to cleave the Asn-Gly peptide linkages as other Asn
or Gln residues can be modiﬁed to their hydroxamic acid
forms [26]. Because the Tα1 peptide does not contain Gln,
Met, or other Asn, chemical heterogeneity dose not occur by
conversion of the Gln or Asn to their hydroxamate forms.
Moreover, there is no possibility of chemical heterogeneity
by conversion of Met to its oxidized forms [27].
After hydroxylamine cleavage, a Gly remained at the
N-terminus of Tα1. However, the natural Tα1h a da n
acetylatedNH-terminal(seeFigure 9).Themolecularweight
diﬀerence between the 2 groups was 15Da, but there was
no signiﬁcant diﬀerence between the 2 bands revealed by
the Gly-SDS-PAGE (see Figure 5). Hence, we used an MS to
analyze the exact molecular weights of the 2 peptides. The
result showed a diﬀerence was 15Da (3123−3108Da) (see
Figure 6), indicating that the concatemer protein was cleaved
satisfactorily.
To investigate the inﬂuence of the extra imino group on
the Tα1, we compared the antitumor and immunomodula-
tion activities between the synthesized Tα1 and the cleaved
Tα1. The results showed no signiﬁcant diﬀerence between
the 2 peptides. Furthermore, we found that Tα1 was able to
depress the prolife ration of HepG2 cells by downregulating
the oxidative stress (data not shown). J¨ ornvall [28]h a d
analyzed 40 known α-amino-acetylated polypeptide chains
and postulated that acetylation occurs during an early
posttranslational stage and may have particular importance
in this regard. However, the structural or functional signiﬁ-
canceoftheN-terminalacetylationofTα1isnotknown,and
a protective function of acetylation with regard to proteolysis
is possible [1]. The change in the N-terminus of cleaved
peptidesmightnotinﬂuencethebioactivityofTα1;however,
it might inﬂuence the stability in vivo.
In summary, Tα1 with a novel structure was prepared via
theexpression andhydroxylamine cleavageofaTα1c o ncat e-
mer protein. This novel Tα1 could perform proliferation of
mice splenic lymphocytes activities, identical to the natural
Tα1. This study would provide the basis for the preparation
of active Tα1 and other peptides.
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